Tag: Boston Scientific
Boston Scientific closes acquisition of Silk Road Medical
Boston Scientific has announced the close of its acquisition of Silk Road Medical—a medical device company that has pioneered a new approach for stroke prevention and...
Boston announces clinical data from chronic pain portfolio at ASPN 2024
Boston Scientific Corporation has announced the presentation of positive five-year pooled results for the Intracept intraosseous nerve ablation system, measuring outcomes across three clinical...
Boston Scientific obtains CE mark for image-guided programming software in DBS
Boston Scientific Corporation has obtained a CE mark for the Vercise neural navigator 5 software with STIMVIEW XT technology, which—when used as part of...
Boston Scientific announces agreement to acquire Silk Road Medical
Boston Scientific has announced that it has entered into a definitive agreement to acquire Silk Road Medical, a medical device company involved in producing...
Boston’s WaveWriter SCS systems gain expanded non-surgical back pain indication from...
Boston Scientific Corporation announced today that the US Food and Drug Administration (FDA) has approved an expanded indication of the company’s WaveWriter spinal cord...
Boston Scientific announces positive WaveWriter SCS findings from SOLIS trial
Boston Scientific Corporation has announced positive one-year results from the SOLIS randomised controlled trial, demonstrating sustained pain relief using its WaveWriter Alpha spinal cord...
Boston Scientific to present late-breaking data at NANS 2024
Boston Scientific Corporation has announced its clinical data that will be featured at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January,...
Axonics announces definitive agreement to be acquired by Boston Scientific
Axonics has announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation for US$71 in cash per share,...
Boston Scientific expands neuromodulation portfolio with Relievant Medsystems acquisition
Boston Scientific Corporation has announced the close of its acquisition of Relievant Medsystems—the company behind the US Food and Drug Administration (FDA)-cleared Intracept intraosseous...
Boston receives expanded US FDA approval of SCS therapy for painful...
Boston Scientific has announced that the US Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha spinal cord stimulator...
Boston Scientific to expand neuromodulation portfolio with Relievant Medsystems acquisition
Boston Scientific Corporation has today announced it has entered into a definitive agreement to acquire Relievant Medsystems—a privately held medical technology company that has...
Boston Scientific announces three-month data from SOLIS trial at NANS
Combination spinal cord stimulation (SCS) therapy with Boston Scientific’s WaveWriter system has demonstrated superior outcomes to conventional medical management (CMM) in chronic pain patients...
TCT 2022: No difference in rates of post-TAVI stroke seen with...
Among patients undergoing transfemoral transcatheter aortic valve implantation (TAVI), the use of a cerebral embolic protection device (Sentinel, Boston Scientific) did not have a...
Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes
A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...
Boston Scientific to present new data on advances in chronic pain...
Boston Scientific has announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA)....
Nevro announces plans to appeal jury decision in spinal cord stimulation...
Nevro Corporation has provided an update on its position following a Delaware jury’s decision to award Boston Scientific US$20 million over patent infringements. The...
Boston Scientific announces agreement to acquire Devoro Medical
Today, Boston Scientific announced an agreement to acquire Devoro Medical, developer of the Wolf thrombectomy platform. The non-console and lytic-free Wolf technology targets and...
Boston Scientific launches FAST—a new therapy for spinal cord stimulation
Boston Scientific has announced the European launch of FAST—a new, fast-acting sub-perception therapy that the company says is clinically proven to demonstrate significant and...
Vercise Genus DBS system received FDA approval
Boston Scientific has announced that it has received US Food and Drug Administration (FDA) approval for its fourth-generation Vercise Genus deep brain stimulation (DBS) system.
According to a company press release, the...
Vercise DBS receives breakthrough device designation from FDA
Functional Neuromodulation has announced that the Vercise deep brain stimulation (DBS) device, developed and manufactured by Boston Scientific, has received breakthrough device designation from...
Boston Scientific announces CE mark approval of the VERCISE Neural Navigator...
Boston Scientific has announced the CE mark approval of the Vercise Neural Navigator 3 directional deep brain stimulation (DBS) programming software—the first system that...
Saluda Medical raises US$75 million equity financing from Boston Scientific and...
Following the announcement of the debt financing with Medtronic, Saluda Medical has announced that it has secured US$75 million in equity financing from Boston...
Spectra WaveWriter spinal cord stimulator system launches in Europe
The launch of the Spectra WaveWriter spinal cord stimulator (SCS; Boston Scientific) system in Europe has been announced. The Spectra WaveWriter SCS system is...
Boston Scientific launches Vercise primary cell and Vercise Gevia deep brain...
The launch of the Vercise primary cell (PC) and Vercise Gevia deep brain stimulation (DBS) systems, featuring the Vercise Cartesia Directional Lead (Boston Scientific)...
Patent litigation update for Nevro–Boston Scientific case
In a press release, Nevro Corp has announced that it has filed with Boston Scientific a joint statement proposing dismissal of the declaratory judgement claims...
Positive late-breaking data from the INTREPID study announced
The one-year data from the INTREPID study, the first and only prospective, double-blind, randomised, sham-controlled, multi-centre study of deep brain stimulation (DBS) for advanced,...
WHISPER SCS study: therapy optimisation associated with more effective pain relief
New data from the WHISPER randomised controlled trial (RCT) have demonstrated that patients who are given the choice to use both sub-perception and paraesthesia-based...
Spectra WaveWriter Spinal Cord Stimulator System receives FDA approval
The Spectra WaveWriter Spinal Cord Stimulator (SCS) System (Boston Scientific) has received FDA approval. It is the first and only system approved by the...
Vercise deep brain stimulation system gains FDA approval
The US Food and Drug Administration (FDA) has approved the Vercise deep brain stimulation (DBS) system (Boston Scientific). DBS is used to treat the symptoms...
No difference in pain relief between 1kHz and 10kHz spinal cord...
A randomised controlled trial has found excellent pain relief and no clinical difference among spinal cord stimulation frequencies from 1kHz–10kHz. Further, the study showed...
CE mark for Vercise Gevia deep brain stimulation system
CE mark has been granted for the Vercise Gevia deep brain stimulation (DBS) system (Boston Scientific), a rechargeable, magnetic resonance (MR) conditional device indicated...
High patient satisfaction levels for spinal cord stimulation over a 7.5-year...
Data from a single centre using a single spinal cord stimulator manufacturer have shown that patients with neuropathic pain treated with spinal cord stimulation...
Nevro files lawsuit for patent infringement against Boston Scientific in the...
Nevro Corp has announced that it has filed a lawsuit for patent infringement against units of Boston Scientific. The lawsuit, filed in the United States...
SCS TechTalk: Innovation Starts Here
In this Boston Scientific Educational Supplement, you will read about the pace of innovation—from delivering the first and only rechargeable spinal cord stimulation (SCS) system powered by intuitive...
Boston Scientific acquires Cosman Medical radiofrequency ablation manufacturer
Boston Scientific Corporation has acquired Cosman Medical a privately-held manufacturer of radiofrequency ablation systems. According to a press release, the Cosman Medical team and...
Boston Scientific receives US FDA approval for Precision Montage MRI spinal...
Boston Scientific Corporation has launched the Precision Montage MRI spinal cord stimulator system after receiving approval from the US Food and Drug Administration (FDA)....
LUMINA data demonstrate 70% greater low back pain relief with Precision...
Final results evaluating the Precision Spectra spinal cord stimulator system (Boston Scientific) demonstrate that the device provides more than 70% greater low back pain...
